SUPPORTING INFORMATION

Activated Microglia Targeting Dendrimer-minocycline Conjugate as Therapeutics for Neuroinflammation

Rishi Sharma¹, Soo-Young Kim¹, Anjali Sharma¹, Zhi Zhang³, Siva Pramodh Kambhampati¹, Sujatha Kannan^{1,3,4,5}, Rangaramanujam M Kannan^{1,2,4,5}

¹Center for Nanomedicine, Department of Ophthalmology, Wilmer Eye Institute Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA;

²Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore MD, 21218, USA;

³Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA;

⁴*Hugo W. Moser Research Institute at Kennedy Krieger, Inc., Baltimore MD, 21205, USA;*

⁵Kennedy Krieger Institute – Johns Hopkins University for Cerebral Palsy Research Excellence, Baltimore, MD 21218, USA;

*Corresponding author:

Rangaramanujam M. Kannan, Arnall Patz Distinguished Professor of Ophthalmology, Center for Nanomedicine at the Wilmer Eye Institute, 400 North Broadway, Baltimore, Maryland 21231, USA

Tel.: +1 443-287-8634; Fax: +1 443-287-8635; e-mail: krangar1@jhmi.edu

Contents

1. Characterization data of intermediates and dendrimer conjugates

Compound 3:



Figure S1. ¹H NMR spectrum of compound 3 (CDCl₃, 500 MHz).



Figure S2. ¹³C{¹H} NMR of compound 3 (CDCl₃, 75 MHz).



Figure S3. HRMS (ESI⁺) spectrum of compound 3.





Figure S4. ¹H NMR spectrum of compound 5 (CD₃OD, 500 MHz).



Figure S5. ¹³C {¹H} NMR of compound 5 (DMSO, 75 MHz)



Figure S6.HRMS (ESI+) spectrum of compound 5



Figure S7. HPLC trace of compound 5





Rishi-B1-53-1Hpp 1H_1D DMSO {C:\data\Kannan} KR_rishi 8 Internal CH₂ ofdendrimer Interior amide protons of dendrimer Surface OH protons ofdendrimer 3.0 3.0 ٣ Ч 3.5 **1**,002.19/1 **5** 488.25 √ 1,060.44√1 5.5 5.0 4.5 f1 (ppm) 8.0 8.0 4.0 37.37 10.0 9.5 9.0 8.5 7.5 7.0 6.5 6.0 2.0 0.5 1.5 1.0

Figure S8. ¹H NMR spectrum of compound 7 (DMSO, 500 MHz).



Figure S9. HPLC trace of compound 7.

Compound 8:



Figure S10. ¹H NMR spectrum of compound 8 (DMSO, 500 MHz).



Figure S11. ¹H NMR spectrum of compound 8 (CD₃OD₃ 500 MHz).



Figure S12. MALDI-TOF trace for compound 8 (DHB matrix).



Figure S13. HPLC trace of compound 8.



Figure S14. DLS size distribution of dendrimer 8 in water at 25°C.

Compound 9:



Figure S15. ¹H NMR spectrum of compound 9 (DMSO, 500 MHz).

Compound 11:



Figure S16. ¹H NMR spectrum of compound 11 (DMSO, 500 MHz).



Figure S17. HPLC trace of compound 11.

Compound 12:





Figure S18. ¹H NMR spectrum of compound 12 (DMSO, 500 MHz).



Figure S19. HPLC trace of compound 12 at 650 nm.